Alexander CS - Search Results

1

Are untimed antiretroviral drug levels useful predictors of adherence behavior?

Liechty CA, Alexander CS, Harrigan PR, Guzman JD, Charlebois ED, Moss AR, Bangsberg DR. Liechty CA, et al. Among authors: alexander cs. AIDS. 2004 Jan 2;18(1):127-9. doi: 10.1097/00002030-200401020-00017. AIDS. 2004. PMID: 15090840

2

A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression.

Gross R, Yip B, Lo Re V 3rd, Wood E, Alexander CS, Harrigan PR, Bangsberg DR, Montaner JS, Hogg RS. Gross R, et al. Among authors: alexander cs. J Infect Dis. 2006 Oct 15;194(8):1108-14. doi: 10.1086/507680. Epub 2006 Sep 12. J Infect Dis. 2006. PMID: 16991085

3

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.

Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, Brumme CJ, Brumme ZL, Mo T, Alexander CS, Montaner JS. Harrigan PR, et al. Among authors: alexander cs. J Infect Dis. 2005 Feb 1;191(3):339-47. doi: 10.1086/427192. Epub 2004 Dec 22. J Infect Dis. 2005. PMID: 15633092 Clinical Trial.

4

Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.

Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, Wood E, Dong WW, Montaner JS, Harrigan PR. Hogg RS, et al. PLoS Med. 2006 Sep;3(9):e356. doi: 10.1371/journal.pmed.0030356. PLoS Med. 2006. PMID: 16984218 Free PMC article.

5

Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease.

Alexander CS, Asselin JJ, Ting LS, Montaner JS, Hogg RS, Yip B, O'Shaughnessy MV, Harrigan PR. Alexander CS, et al. J Infect Dis. 2003 Aug 15;188(4):541-8. doi: 10.1086/376835. Epub 2003 Jul 29. J Infect Dis. 2003. PMID: 12898441 Clinical Trial.

6

Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.

Harrigan PR, Hertogs K, Verbiest W, Pauwels R, Larder B, Kemp S, Bloor S, Yip B, Hogg R, Alexander C, Montaner JS. Harrigan PR, et al. AIDS. 1999 Oct 1;13(14):1863-71. doi: 10.1097/00002030-199910010-00008. AIDS. 1999. PMID: 10513644

7

Selection of drug-resistant HIV.

Harrigan PR, Alexander CS. Harrigan PR, et al. Among authors: alexander cs. Trends Microbiol. 1999 Mar;7(3):120-3. doi: 10.1016/s0966-842x(99)01467-5. Trends Microbiol. 1999. PMID: 10203841 Review.

8

Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users.

Alexander CS, Dong W, Schechter MT, O'Shaughnessy MV, Strathdee SA, Mo T, Montaner JS, Harrigan PR. Alexander CS, et al. AIDS. 1999 May 28;13(8):981-5. doi: 10.1097/00002030-199905280-00015. AIDS. 1999. PMID: 10371180

9

HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort.

Alexander CS, Dong W, Chan K, Jahnke N, O'Shaughnessy MV, Mo T, Piaseczny MA, Montaner JS, Harrigan PR. Alexander CS, et al. AIDS. 2001 Mar 30;15(5):601-7. doi: 10.1097/00002030-200103300-00009. AIDS. 2001. PMID: 11316997

10

Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.

Harrigan PR, Hertogs K, Verbiest W, Larder B, Yip B, Brumme ZL, Alexander C, Tilley J, O'Shaughnessy MV, Montaner JS. Harrigan PR, et al. Antivir Ther. 2003 Oct;8(5):395-402. Antivir Ther. 2003. PMID: 14640386 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters